DNA Sequencing: Latest Developments In Next-Generation Sequencing By Andrew Szopa-Comley Next-generation sequencing has expanded the frontiers of genomic research, opening up new avenues of enquiry and offering insights into diverse areas of biology. Rapid developments in this field are dramatically lowering costs and increasing speeds. With the arrival… Read More
Cell Migration: Probing Cell Movement With Smarter Tools By Dr John Comley Cell migration comprises the movement of cells from one location to another in response to events, biological signals or environmental cues. Cell migration plays a critical role in numerous normal biological processes and also in many diseases. Most… Read More
Nanobioscience & Nanotechnology: The Future Of Personalised Medicine By Abhishek Gottipati, Joseph M. Sanders and Dr Scott A. Tenenbaum Nanotechnology has been more than a buzz word in the business world for a long time now and has been striding ahead, living up to the hype. There is a general… Read More
Innovate While Derisking Drug Development: Yes We Can! Taher Abbasi, Pradeep Fernandes, Dr Shireen Vali and Professor Gurkirpal Singh The outlook for the drug industry continues to remain bleak in context of productivity and success rates. In spite of ongoing increase in R&D expenses and technology revolutions in the genomics… Read More
Combining chemists expertise and a computer's advanced capabilities to generate good ideas. By Dr Matthew Segall, Edmund Champness, Dr Chris Leeding, Dr Ryan Lilien, Dr Ramgopal Mettu and Dr Brian Stevens Drug One of the defining challenges of drug discovery is the need to make complex decisions regarding the design… Read More
Free Online Resources Enabling Crowd-Sourced Drug Discovery By Dr Antony J. Williams, Valery Tkachenko, Dr Chris Lipinski, Professor Alexander Tropsha and Dr Sean Ekins The availability of freely accessible online resources to enable and support drug discovery has blossomed in recent years. The PubChem platform is now accompanied by a… Read More
Himarnessing fragment-based drug discovery at CRT By Dr Andrew P Turnbull and Dr Martin E Swarbrick In the past decade, fragment-based drug discovery (FBDD) has gained increasing popularity in the pharmaceutical industry as a powerful alternative and complement to traditional high-throughput screening (HTS) as a source of preliminary hits for… Read More
Letting the Target Determine your Compound Acquisition Strategy By Dr John Harris With compound libraries likely to remain the cornerstone of hit and lead discovery for the foreseeable future, this paper seeks to summarise current and future approaches to optimal library design and compound acquisition, using examples and experimental evidence… Read More
Growing Interest in Outsourcing Ion Channel Services By Dr John Comley Summer 2008 Significant demand now exists in Pharma and Biotech to access ion channel testing services and this is reflected by the number and the variety of service offerings. In the highly competitive area of cardiac safety hERG testing… Read More
Integrating HTS and Fragment-based Drug Discovery By Dr John Barker, Dr Thomas Hesterkamp and Dr Mark Whittaker High-Throughput Screening and Fragment Based Drug Discovery have been considered as alternative approaches to drug discovery for enzyme targets. HTS tends to be a rather quick way of identifying potent chemical matter with… Read More
Trends in the microRNA Marketplace By Kathy Gray and Dr Enal Razvi In this article, a recent market analysis is discussed aimed at understanding the market landscape, trends and opportunity in the rapidly-expanding microRNA marketplace. These market analyses are presented in detail in a recently published MicroRNA 2008 market report. Read More
Progress in Systems-Based Analysis of Cellular Signalling By Dr Jeffrey A. Radding Drug discovery currently focuses on targeted approaches, relying on validation of the target as a disease driver. However, the underlying biological complexity of disease often frustrates these attempts at therapeutic intervention, resulting in high failure rates due to… Read More
Perspectives for ADMET Integration in the Discovery Process By Dr Constance Hofer ADMET (ADME/Tox), is a relatively new symbiotic acronym for the investigation of basic compound behaviour in terms of absorption, distribution, metabolism and excretion, combined with assessments of toxicity. The emergence of ADMET instead of ADME reflects the growing… Read More
Technology, Bane or Bonanza for the Pharmaceutical industry? By Dr Stephen Naylor, Adam W. Culbertson and Dr Stephen J. Valentine Productivity in the pharmaceutical industry has long held well-documented concerns. While the adoption of new technologies into the drug discovery and development process has often been seen as a… Read More
Personalised Medicine - Technological innovation and patient empowerment or exuberant hyperbole? By Adam W. Culbertson, Dr Stephen J. Valentine and Dr Stephen Naylor The current paradigm of modern healthcare focuses on patient symptoms, subsequent diagnosis and corresponding treatment of the specific disease(s). Escalating healthcare costs and a trial and error… Read More
The Role of Repositioning in Drug Discovery and Development By Dr Louis A. Tartaglia and Dr Lee E. Babiss The large number of drug candidate failures in recent years has been enormously costly for the pharmaceutical industry, but has also created the tremendous opportunity of repositioning these molecules into new… Read More